The FinancialContent Network     SocialPicks Community   |   MarketMinute Monitor   |   MarketMinute Market Updates   |   MarketMinute Stock News
SocialPicks
   Sign Up   |   Log In   |   What is SocialPicks?     

 Auxilium Pharmaceuticals Inc.  (AUXL) Trade Now »     Rate AUXL  -  Discuss AUXL  -  Add to Watch List         Graphic_subscribe

       Sector: Healthcare  >  Industry: Biotechnology & Drugs
SocialPicks Sentiment:

** v.s. other stocks 		This Quarter's Sentiment:
All:
92.5%
Top:
100.0%
Rate AUXL:



AUXL Analysis & Videos »


AUXL: Bull or Bear?

Rating: Positive Negative Neutral/Hold Auxilium Pharmaceuticals Inc. Graphic_rating_buy AUXL
Foto
62%
 +29.36%
in 181 days
<>

On 4/28/09, the FDA accepted for priority review (six-month) Auxilium's (NASDAQ:AUXL) BLA for Xiaflex (clostridial collagenase for injection) for the treatment of Dupuytren's contracture. AUXL filed the BLA on 2/27/09 and included data from 1,082 subjects and over 2,600 injections. The PDUFA decision date is 8/28/09 for the Xiaflex BLA. If approved by the FDA, AUXL plans to launch Xiaflex in the U.S. within 60 days during 2H09.

<> <> On 2/2/09, AUXL announced the completion of enrollment in a randomized, double-blind, placebo-controlled U.S. Phase 2b clinical trial for Xiafle...
By  Marian Filo   (-24.55%  risk: aggressive)  06/10/09 Comment


Updated Clinical Trial and FDA Decision Calendars Graphic_rating_buy AUXL
Mikerun
73%
 +27.44%
in 279 days

Updated FDA and Clinical Trial Calendars    

Posted by: Mike Havrilla in Untagged   on Mar 04, 2009  

<!-- Post Teaser Text --> <> Below are some recent updates to the BioMedReports.com -- FDA and Clinical Trial Calendars :  <> 1.) Auxilium Pharma (AUXL): 3/2/09 BLA submission with priority review request for XIAFLEX (clostridial collagenase for injection), a novel, first-in-class, orphan-designated biologic for the treatment of Dupuytren's contracture. 5/2/09 is the date for FDA to accept the filing for review and decide on priority revi...
By  Mike Havrilla   (+1.04%  risk: conservative)  03/04/09 Comment


Fair Value on Auxilium Pharma AUXL
-6.95%
in 550 days
The fundamentals at Auxilium are solid, but the lofty valuation keeps us from recommending the name at this level.
By  Zacks.com   (-12.82%  risk: moderate)  06/05/08 Comment


Get free stock alert for AUXL:
Your Email Address:


The Name Brand Drug Revolution Graphic_rating_buy AUXL
Dcgicon
50%
 +14.03%
in 613 days

These guys are an in the midst of a major recovery.

I wish I would have had the chance to buy them while they were falling earlier in the year.

Medical is the only business without a market. Each medical IP stock has a virtual lock down on revenues for the length of life of the IP.

These guys are part of the new world order mental landscape painted in pigments and oil bases made of psychotropic chemical substances.

By  David Caro-Greene   (-4.61%  risk: moderate)  04/03/08 Comment





People Bullish on AUXL

Foto
Marian Filo
Principal
62%
6 mos ago

Mikerun
Mike Havrilla
Principal
73%
9 mos ago

Dcgicon
David Caro-Greene
Sr. Analyst
50%
about 1 year ago

Spoon_ga_ga_ga_ga_ga
bluejetty
Sr. Analyst
21%
about 1 year ago

Venom
sodipodium
Analyst
37%
over 2 years ago


People Bearish on AUXL

ROCK-STAR INVESTORS
Rank Name Sharpe Ratio Avg Return Followers
1 noshoes 21.10 +34.63% 381
2 Gerald Greene 18.14 +67.11% 211
3 stockmarketfunding.com 17.66 +25.66% 55
4 akiralegrand 13.47 +14.32% 62
5 anup2104 12.13 +74.38% 40


POPULAR STOCKS
Symbol Company Name Sentiment
AIG American International Group Inc.
JNJ Johnson & Johnson
BAC Bank of America Corp
INTC Intel Corp
RIMM Research in Motion Ltd
GLD streetTRACKS Gold

TODAY'S HEADLINES

TODAY'S TOP PICKS

 

StreetInsider.com on AUXL


Discussion Wall + Add  

Be the first to start a discussion and earn 2 points.



More Resources

Graphic_arrow1 About Auxilium Pharmaceuticals Inc. - Answers.com

Graphic_arrow1 Historical Prices - Yahoo

Graphic_arrow1 Message Boards - BoardCentral.com

Graphic_arrow1 More Info:     Yahoo   |   Google   |   Reuters




IN THE PRESS
Press_forbes Press_washingtonpost Press_wsj Press_npr Press_techcrunch